Lindsey R. Baden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lindsey R. Baden has a total of 612 co-authors. Here are the top co-authors by number of shared publications:
- Nadine Rouphael
Hope Clinic, Emory University, Decatur, USA
9 shared publications - Ofer Levy
Precision Vaccines Program, Boston Children’s Hospital, Harvard Medical School, Boston, USA
8 shared publications - Al Ozonoff
Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA
7 shared publications - Annmarie Hoch
Clinical and Data Coordinating Center (CDCC) Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
7 shared publications - Florian Krammer
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
7 shared publications - Hana M. El Sahly
Baylor College of Medicine
7 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDistinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants
- Open Access
- 28 September 2026
- Published by Elsevier in American Journal of Transplantation
Real-world evaluation of recombinant zoster vaccine uptake and outcomes in solid organ transplant recipients: A retrospective cohort study
- 28 September 2026
- Published by Elsevier in American Journal of Transplantation
Open AccessReal-world evaluation of recombinant zoster vaccine uptake and outcomes in solid organ transplant recipients: A retrospective cohort study
- Open Access
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 700-711
Virus reactivation in acute and long COVID-19
- 5 August 2026
- Published by Springer Nature in Nature
- Vol. 656 (8128) , 700-711
Open AccessVirus reactivation in acute and long COVID-19
- Open Access
- 20 July 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (8) , e1977
Reactogenicity and Immunogenicity of Adjuvanted and Nonadjuvanted RSV Vaccines in Solid Organ Transplant Recipients
Background.: Solid organ transplant (SOT) recipients are at high risk for severe respiratory syncytial virus (RSV). While RSV vaccine immunogenicity data in transplant populations are emerging, questions remain regarding the magnitude and durability of responses, cellular immunity, and determinants of decreased response. Methods.: We conducted a prospective, single-center cohort study evaluating RSV vaccine reactogenicity and immunogenicity in SOT recipients compared with healthy controls. Serum was collected pre-vaccination and at 1, 3, and 6 mo post-vaccine to measure anti-fusion glycoprotein antibodies to RSV A and B and anti-nucleocapsid antibodies as a marker of natural infection. Peripheral blood mononuclear cells were collected from a subset for RSV-fusion (F)-specific cellular analyses. Results.: Forty-three SOT recipients (median age, 65) and 16 controls were enrolled (from October 2023 to January 2024). Mild reactogenicity occurred in ~25% of participants, with no severe events. In SOT recipients, anti-fusion glycoprotein IgG, RSV-F-specific CD4 + and CD8 + T cells increased significantly at 1 mo ( P < 0.01), with similar antibody fold changes to controls. Antibody responses remained durable through 6 mo; the rate of decline did not differ significantly between groups. Mycophenolate use was inversely correlated with antibody titers ( P < 0.05); vaccine type, organ, and time from transplant were not. The adjuvanted vaccine induced greater RSV-F-specific CD4 + T-cell responses at 3 mo. One SOT recipient developed RSV during the study. Conclusions.: RSV vaccination was well tolerated and immunogenic in SOT recipients. Further research should optimize vaccination strategies and ideal timing for booster doses.
- 20 July 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (8) , e1977
Open AccessReactogenicity and Immunogenicity of Adjuvanted and Nonadjuvanted RSV Vaccines in Solid Organ Transplant Recipients
Background.: Solid organ transplant (SOT) recipients are at high risk for severe respiratory syncytial virus (RSV). While RSV vaccine immunogenicity data in transplant populations are emerging, questions remain regarding the magnitude and durability of responses, cellular immunity, and determinants of decreased response. Methods.: We conducted a prospective, single-center cohort study evaluating RSV vaccine reactogenicity and immunogenicity in SOT recipients compared with healthy controls. Serum was collected pre-vaccination and at 1, 3, and 6 mo post-vaccine to measure anti-fusion glycoprotein antibodies to RSV A and B and anti-nucleocapsid antibodies as a marker of natural infection. Peripheral blood mononuclear cells were collected from a subset for RSV-fusion (F)-specific cellular analyses. Results.: Forty-three SOT recipients (median age, 65) and 16 controls were enrolled (from October 2023 to January 2024). Mild reactogenicity occurred in ~25% of participants, with no severe events. In SOT recipients, anti-fusion glycoprotein IgG, RSV-F-specific CD4 + and CD8 + T cells increased significantly at 1 mo ( P < 0.01), with similar antibody fold changes to controls. Antibody responses remained durable through 6 mo; the rate of decline did not differ significantly between groups. Mycophenolate use was inversely correlated with antibody titers ( P < 0.05); vaccine type, organ, and time from transplant were not. The adjuvanted vaccine induced greater RSV-F-specific CD4 + T-cell responses at 3 mo. One SOT recipient developed RSV during the study. Conclusions.: RSV vaccination was well tolerated and immunogenic in SOT recipients. Further research should optimize vaccination strategies and ideal timing for booster doses.
- Open Access
- 16 March 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (4) , 1100-1112
Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19
Azithromycin is a widely used antibiotic and was frequently used to treat hospitalized patients during the COVID-19 pandemic. The impact of empiric azithromycin use on the respiratory microbiome in patients with viral respiratory infections is unclear. Here we used longitudinal metatranscriptomics on nasal swabs from a prospective multicentre cohort of 1,164 patients hospitalized for COVID-19. We compared the upper respiratory microbiome, resistome and systemic immune response in patients treated with azithromycin ( n = 366) with those who received no antibiotics ( n = 474) or other antibiotics ( n = 324). We found that azithromycin altered microbiome composition and increased the expression and relative proportion of macrolide/lincosamide/streptogramin (MLS) resistance genes. These changes occurred after 1 day of exposure and persisted for over a week. MLS resistance gene expression was associated with commensals and potential pathogens, while there were no differences in host inflammatory gene expression in blood and airways. This demonstrates that empiric azithromycin treatment impacts the upper respiratory microbiome and resistome without apparent anti-inflammatory benefit.
- 16 March 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (4) , 1100-1112
Open AccessEmpiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19
Azithromycin is a widely used antibiotic and was frequently used to treat hospitalized patients during the COVID-19 pandemic. The impact of empiric azithromycin use on the respiratory microbiome in patients with viral respiratory infections is unclear. Here we used longitudinal metatranscriptomics on nasal swabs from a prospective multicentre cohort of 1,164 patients hospitalized for COVID-19. We compared the upper respiratory microbiome, resistome and systemic immune response in patients treated with azithromycin ( n = 366) with those who received no antibiotics ( n = 474) or other antibiotics ( n = 324). We found that azithromycin altered microbiome composition and increased the expression and relative proportion of macrolide/lincosamide/streptogramin (MLS) resistance genes. These changes occurred after 1 day of exposure and persisted for over a week. MLS resistance gene expression was associated with commensals and potential pathogens, while there were no differences in host inflammatory gene expression in blood and airways. This demonstrates that empiric azithromycin treatment impacts the upper respiratory microbiome and resistome without apparent anti-inflammatory benefit.
- Open Access
- 23 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 125
Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
- 23 February 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 125
Open AccessAuthor Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
- Open Access
- 7 January 2026
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 26 (5) , 497-509
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
- 7 January 2026
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 26 (5) , 497-509
Open AccessSafety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
- Open Access
- 3 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 1
Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
Background The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will develop long COVID is challenging due to the absence of established biomarkers, clear disease mechanisms, or well-defined sub-phenotypes. Machine learning (ML) models may address this gap by leveraging clinical data to enhance diagnostic precision. Methods Clinical data, including antibody titers and viral load measurements collected at the time of hospital admission, are used to predict the likelihood of acute COVID-19 progressing to long COVID. Machine learning models are trained and evaluated for predictive performance. Feature importance analysis is performed to identify the most influential predictors. Results The machine learning models achieve median AUROC values ranging from 0.64 to 0.66 and AUPRC values between 0.51 and 0.54, demonstrating predictive capabilities. Low antibody titers and high viral loads at hospital admission emerge as the strongest predictors of long COVID outcomes. Comorbidities—such as chronic respiratory, cardiac, and neurologic diseases—and female sex are also identified as significant risk factors. Conclusions Machine learning models identify patients at risk for developing long COVID based on baseline clinical characteristics. These models guide early interventions, improve patient outcomes, and mitigate the long-term public health impacts of SARS-CoV-2.
- 3 January 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1) , 1
Open AccessMachine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
Background The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will develop long COVID is challenging due to the absence of established biomarkers, clear disease mechanisms, or well-defined sub-phenotypes. Machine learning (ML) models may address this gap by leveraging clinical data to enhance diagnostic precision. Methods Clinical data, including antibody titers and viral load measurements collected at the time of hospital admission, are used to predict the likelihood of acute COVID-19 progressing to long COVID. Machine learning models are trained and evaluated for predictive performance. Feature importance analysis is performed to identify the most influential predictors. Results The machine learning models achieve median AUROC values ranging from 0.64 to 0.66 and AUPRC values between 0.51 and 0.54, demonstrating predictive capabilities. Low antibody titers and high viral loads at hospital admission emerge as the strongest predictors of long COVID outcomes. Comorbidities—such as chronic respiratory, cardiac, and neurologic diseases—and female sex are also identified as significant risk factors. Conclusions Machine learning models identify patients at risk for developing long COVID based on baseline clinical characteristics. These models guide early interventions, improve patient outcomes, and mitigate the long-term public health impacts of SARS-CoV-2.
- 24 October 2025
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 11 (1) , 1-17
Acute SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory pathogen that emerged in December 2019 and caused a global pandemic by March 2020, with >7 million deaths due to coronavirus disease 2019 (COVID-19) globally as of September 2025. The clinical syndrome of COVID-19 ranges from asymptomatic infection to severe disease with pneumonia and death. SARS-CoV-2 variant type, inoculum, previous exposure and host factors influence the clinical trajectory. Identification of key structural proteins of SARS-CoV-2 and insights into the pathophysiology of the immune response to infection led to the development of effective preventive (vaccines and monoclonal antibodies) and therapeutic (antivirals and immunomodulatory agents) agents. Antiviral agents, such as remdesivir and nirmatrelvir-ritonavir, inhibit viral replication and immunomodulatory agents, such as tocilizumab and baricitinib, act to reduce a dysregulated immune response to SARS-CoV-2. The pandemic had economic and socio-cultural consequences that affected the quality of life and overall life expectancy of individuals. As the emergency phase of the pandemic concludes, robust monitoring and surveillance systems must be sustained and research to improve vaccines and therapeutics must continue to maintain control of SARS-CoV-2 in the population and be prepared for emerging pathogens with pandemic potential.
- 24 October 2025
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 11 (1) , 1-17
Acute SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory pathogen that emerged in December 2019 and caused a global pandemic by March 2020, with >7 million deaths due to coronavirus disease 2019 (COVID-19) globally as of September 2025. The clinical syndrome of COVID-19 ranges from asymptomatic infection to severe disease with pneumonia and death. SARS-CoV-2 variant type, inoculum, previous exposure and host factors influence the clinical trajectory. Identification of key structural proteins of SARS-CoV-2 and insights into the pathophysiology of the immune response to infection led to the development of effective preventive (vaccines and monoclonal antibodies) and therapeutic (antivirals and immunomodulatory agents) agents. Antiviral agents, such as remdesivir and nirmatrelvir-ritonavir, inhibit viral replication and immunomodulatory agents, such as tocilizumab and baricitinib, act to reduce a dysregulated immune response to SARS-CoV-2. The pandemic had economic and socio-cultural consequences that affected the quality of life and overall life expectancy of individuals. As the emergency phase of the pandemic concludes, robust monitoring and surveillance systems must be sustained and research to improve vaccines and therapeutics must continue to maintain control of SARS-CoV-2 in the population and be prepared for emerging pathogens with pandemic potential.
- Open Access
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomized, placebo-controlled trial
Background: Current whole-cell killed oral cholera vaccines have utility but require multiple doses and have limited efficacy in young children. PanChol is a single-dose live-attenuated cholera vaccine derived from the current seventh pandemic Vibrio cholerae O1 strain. It co-expresses Inaba and Ogawa antigens, over-expresses the non-toxic cholera toxin B subunit, and is designed to minimize reactogenicity and prevent toxigenic reversion. We assessed safety and immunogenicity in a first-in-human trial. Methods: In a dose-escalation phase at Brigham and Women’s Hospital (Boston, MA, USA), seven cohorts received one dose of 10 4 -10 10 colony-forming-units (CFU) PanChol. Two dosing groups of 2×10 7 and 2×10 8 were subsequently evaluated in a double-blind, placebo-controlled module. Fecal shedding was assessed until day five; safety and immunogenicity were monitored for six months. This trial is registered with ClinicalTrials.gov , NCT05657782 . Findings: Between Dec 2022 and Feb 2025, 57 healthy adults were enrolled (dose-escalation: n=21; expansion n=28 vaccine and n=8 placebo recipients). PanChol was safe and well-tolerated at all doses, and no safety concerns were identified including no vaccine-related serious adverse events. In the dose-escalation phase, 81% (17/21) of participants had 39 unsolicited adverse events (AE). In the randomized module, at least one AE occurred in 64% (9/14) at 10 7 dose and in all 10 8 (13/13) and placebo (7/7) recipients. Most AEs were mild and only four were >grade 2 (all unrelated to vaccine). Shedding was detected in 44 recipients of ≥10 5 CFU, with no relationship to dose. All 45 vaccinees given ≥10 5 CFU seroconverted vibriocidal antibodies to both serotypes, with comparable mean titers across doses. IgM responses targeting Inaba or Ogawa polysaccharides were detected in 44 and 41 vaccinees respectively, and anti-toxin IgG responses were measured in 21 vaccinees. Antibody lymphocyte supernatant assays demonstrated mucosal IgA to these antigens and to colonization factor, TcpA. Interpretation: A single oral dose of PanChol induced 100% vibriocidal seroconversion over a 100,000-fold dose range with no safety concerns. These findings support further development of PanChol as a new tool for cholera prevention, including studies in endemic settings and in children. Funding: Wellcome Trust. Research in context: Evidence before this study: Cholera remains a global public health threat; killed oral cholera vaccines (OCVs) are important for control. However, they have limited efficacy in young children and require multiple doses for maximum efficacy. Live-attenuated OCVs, like natural infection, may induce protective immunity with a single dose. While other live-attenuated OCVs have been developed, none are WHO prequalified. We searched PubMed from inception to July 2025 for studies evaluating OCVs using the terms “live oral cholera vaccine trial O1”, yielding 25 non-review clinical trial articles. All tested live vaccines were derived from the extinct classical V. cholerae biotype or early El Tor biotype strains and were Inaba serotype. None were engineered to be resistant to reversion to toxigenicity. Added value of this study: This first-in-human trial establishes that PanChol, a live-attenuated OCVs engineered from the current global pandemic El Tor V. cholerae O1 strain, is safe and immunogenic in an adult population in Boston, USA. Unlike previous live-attenuated vaccines, PanChol expresses both Inaba and Ogawa serotype antigens, is engineered for enhanced genetic stability, and resists toxigenic reversion. PanChol shedding, a marker for vaccine replication in the intestine, was detectable across doses 10 5 -10 10 CFU. Whole genome sequencing of PanChol isolated from vaccinees’ stool confirmed the vaccine’s genomic stability. Across all doses, 100% of vaccinees seroconverted to both Inaba and Ogawa serotypes, demonstrating potent immunogenicity. Implications of all the available evidence: PanChol’s favorable safety profile and immunogenicity support additional development as a new agent for cholera control. Since PanChol is derived from the current pandemic strain, and natural infection stimulates more potent immunity to cholera than killed vaccines, PanChol may offer effective single-dose protection for children. It may be beneficial for reactive vaccination campaigns and for alleviating the global shortage of killed OCVs. These positive results warrant the establishment of the vaccine’s safety and immunogenicity in cholera endemic settings and age de-escalation trials.
Open AccessSafety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomized, placebo-controlled trial
Background: Current whole-cell killed oral cholera vaccines have utility but require multiple doses and have limited efficacy in young children. PanChol is a single-dose live-attenuated cholera vaccine derived from the current seventh pandemic Vibrio cholerae O1 strain. It co-expresses Inaba and Ogawa antigens, over-expresses the non-toxic cholera toxin B subunit, and is designed to minimize reactogenicity and prevent toxigenic reversion. We assessed safety and immunogenicity in a first-in-human trial. Methods: In a dose-escalation phase at Brigham and Women’s Hospital (Boston, MA, USA), seven cohorts received one dose of 10 4 -10 10 colony-forming-units (CFU) PanChol. Two dosing groups of 2×10 7 and 2×10 8 were subsequently evaluated in a double-blind, placebo-controlled module. Fecal shedding was assessed until day five; safety and immunogenicity were monitored for six months. This trial is registered with ClinicalTrials.gov , NCT05657782 . Findings: Between Dec 2022 and Feb 2025, 57 healthy adults were enrolled (dose-escalation: n=21; expansion n=28 vaccine and n=8 placebo recipients). PanChol was safe and well-tolerated at all doses, and no safety concerns were identified including no vaccine-related serious adverse events. In the dose-escalation phase, 81% (17/21) of participants had 39 unsolicited adverse events (AE). In the randomized module, at least one AE occurred in 64% (9/14) at 10 7 dose and in all 10 8 (13/13) and placebo (7/7) recipients. Most AEs were mild and only four were >grade 2 (all unrelated to vaccine). Shedding was detected in 44 recipients of ≥10 5 CFU, with no relationship to dose. All 45 vaccinees given ≥10 5 CFU seroconverted vibriocidal antibodies to both serotypes, with comparable mean titers across doses. IgM responses targeting Inaba or Ogawa polysaccharides were detected in 44 and 41 vaccinees respectively, and anti-toxin IgG responses were measured in 21 vaccinees. Antibody lymphocyte supernatant assays demonstrated mucosal IgA to these antigens and to colonization factor, TcpA. Interpretation: A single oral dose of PanChol induced 100% vibriocidal seroconversion over a 100,000-fold dose range with no safety concerns. These findings support further development of PanChol as a new tool for cholera prevention, including studies in endemic settings and in children. Funding: Wellcome Trust. Research in context: Evidence before this study: Cholera remains a global public health threat; killed oral cholera vaccines (OCVs) are important for control. However, they have limited efficacy in young children and require multiple doses for maximum efficacy. Live-attenuated OCVs, like natural infection, may induce protective immunity with a single dose. While other live-attenuated OCVs have been developed, none are WHO prequalified. We searched PubMed from inception to July 2025 for studies evaluating OCVs using the terms “live oral cholera vaccine trial O1”, yielding 25 non-review clinical trial articles. All tested live vaccines were derived from the extinct classical V. cholerae biotype or early El Tor biotype strains and were Inaba serotype. None were engineered to be resistant to reversion to toxigenicity. Added value of this study: This first-in-human trial establishes that PanChol, a live-attenuated OCVs engineered from the current global pandemic El Tor V. cholerae O1 strain, is safe and immunogenic in an adult population in Boston, USA. Unlike previous live-attenuated vaccines, PanChol expresses both Inaba and Ogawa serotype antigens, is engineered for enhanced genetic stability, and resists toxigenic reversion. PanChol shedding, a marker for vaccine replication in the intestine, was detectable across doses 10 5 -10 10 CFU. Whole genome sequencing of PanChol isolated from vaccinees’ stool confirmed the vaccine’s genomic stability. Across all doses, 100% of vaccinees seroconverted to both Inaba and Ogawa serotypes, demonstrating potent immunogenicity. Implications of all the available evidence: PanChol’s favorable safety profile and immunogenicity support additional development as a new agent for cholera control. Since PanChol is derived from the current pandemic strain, and natural infection stimulates more potent immunity to cholera than killed vaccines, PanChol may offer effective single-dose protection for children. It may be beneficial for reactive vaccination campaigns and for alleviating the global shortage of killed OCVs. These positive results warrant the establishment of the vaccine’s safety and immunogenicity in cholera endemic settings and age de-escalation trials.